Phase 2 Study of Cadonilimab, LM-302, and S-1 with Intraperitoneal Paclitaxel for Treating Claudin 18.2-positive Gastric Cancer with Peritoneal Spread

What this Trial Is About

This trial investigates a combination treatment for patients with Claudin 18.2-positive gastric cancer that has spread to the peritoneum. The study is a phase 2 clinical trial evaluating the use of Cadonilimab, LM-302, S-1, and intraperitoneal paclitaxel in this group of patients. It aims to assess the treatments impact on survival and response in this advanced cancer setting. Participants receive Cadonilimab 10 mgkg and LM-302 2.0 mgkg through intravenous infusion on the first day of each cycle. They also receive paclitaxel 20 mgm2 by intraperitoneal infusion on Days 1 and 8, combined with oral S-1 80 mgm2 taken daily for 14 consecutive days. Each cycle lasts three weeks, and the regimen is repeated as part of the treatment plan. Throughout the study, participants undergo regular monitoring to evaluate 1-year survival rate, treatment-related side effects, tumor response, pathological complete response after surgery, duration of response, progression-free survival, and overall survival. These assessments may occur over periods up to 24 to 36 months. Safety and efficacy data are collected to understand how well the treatment works and its impact on patient health.

Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis